Compare Procter & Gamble Health with Cadila Healthcare - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PROCTER & GAMBLE HEALTH vs CADILA HEALTHCARE - Comparison Results

PROCTER & GAMBLE HEALTH     Change

Merck, the Indian arm of Merck KgaA (Germany), is a relatively smaller player among MNC pharma majors in the country. Merck has two business segments namely Pharmaceuticals and Chemicals. The pharmaceutical business, accounting for 68% of total sales... More

CADILA HEALTHCARE 
   Change

Cadila Healthcare is one of the leading players in the Indian pharma market having a presence in both the domestic and international markets. In the international markets, the company had adopted the strategy of competing directly in the generics mar... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PROCTER & GAMBLE HEALTH CADILA HEALTHCARE PROCTER & GAMBLE HEALTH/
CADILA HEALTHCARE
 
P/E (TTM) x 52.7 14.4 365.2% View Chart
P/BV x 4.8 2.8 169.3% View Chart
Dividend Yield % 10.0 1.5 683.5%  

Financials

 PROCTER & GAMBLE HEALTH   CADILA HEALTHCARE
EQUITY SHARE DATA
    PROCTER & GAMBLE HEALTH
Dec-18
CADILA HEALTHCARE
Mar-18
PROCTER & GAMBLE HEALTH/
CADILA HEALTHCARE
5-Yr Chart
Click to enlarge
High Rs3,549558 636.0%   
Low Rs1,301362 360.0%   
Sales per share (Unadj.) Rs511.4116.3 439.8%  
Earnings per share (Unadj.) Rs61.317.9 343.0%  
Cash flow per share (Unadj.) Rs74.023.1 320.0%  
Dividends per share (Unadj.) Rs440.003.50 12,571.4%  
Dividend yield (eoy) %18.10.8 2,383.2%  
Book value per share (Unadj.) Rs927.885.4 1,086.2%  
Shares outstanding (eoy) m16.601,023.74 1.6%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.74.0 119.9%   
Avg P/E ratio x39.625.7 153.8%  
P/CF ratio (eoy) x32.819.9 164.9%  
Price / Book Value ratio x2.65.4 48.6%  
Dividend payout %717.919.6 3,665.0%   
Avg Mkt Cap Rs m40,257470,664 8.6%   
No. of employees `0001.111.8 9.6%   
Total wages/salary Rs m1,31318,545 7.1%   
Avg. sales/employee Rs Th7,486.710,072.7 74.3%   
Avg. wages/employee Rs Th1,157.61,569.1 73.8%   
Avg. net profit/employee Rs Th897.21,547.7 58.0%   
INCOME DATA
Net Sales Rs m8,490119,049 7.1%  
Other income Rs m2441,132 21.5%   
Total revenues Rs m8,734120,181 7.3%   
Gross profit Rs m1,48228,475 5.2%  
Depreciation Rs m2115,388 3.9%   
Interest Rs m0911 0.0%   
Profit before tax Rs m1,51423,308 6.5%   
Minority Interest Rs m0628 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m660-   
Tax Rs m5635,644 10.0%   
Profit after tax Rs m1,01718,292 5.6%  
Gross profit margin %17.523.9 73.0%  
Effective tax rate %37.124.2 153.4%   
Net profit margin %12.015.4 78.0%  
BALANCE SHEET DATA
Current assets Rs m15,34382,005 18.7%   
Current liabilities Rs m1,96060,720 3.2%   
Net working cap to sales %157.617.9 881.7%  
Current ratio x7.81.4 579.6%  
Inventory Days Days4973 66.6%  
Debtors Days Days2898 28.9%  
Net fixed assets Rs m1,20983,703 1.4%   
Share capital Rs m1661,024 16.2%   
"Free" reserves Rs m15,23586,421 17.6%   
Net worth Rs m15,40187,445 17.6%   
Long term debt Rs m025,551 0.0%   
Total assets Rs m17,595180,653 9.7%  
Interest coverage xNM26.6-  
Debt to equity ratio x00.3 0.0%  
Sales to assets ratio x0.50.7 73.2%   
Return on assets %5.810.6 54.4%  
Return on equity %6.620.9 31.6%  
Return on capital %10.322.0 46.7%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m1,63642,683 3.8%   
Fx outflow Rs m4,36811,242 38.9%   
Net fx Rs m-2,73231,441 -8.7%   
CASH FLOW
From Operations Rs m-1,3049,193 -14.2%  
From Investments Rs m12,697-9,737 -130.4%  
From Financial Activity Rs m-301515 -58.3%  
Net Cashflow Rs m11,093-29 -38,251.4%  

Share Holding

Indian Promoters % 0.0 74.8 -  
Foreign collaborators % 51.8 0.0 -  
Indian inst/Mut Fund % 18.2 8.3 219.3%  
FIIs % 1.0 5.9 16.9%  
ADR/GDR % 0.0 0.0 -  
Free float % 29.1 11.0 264.5%  
Shareholders   28,591 44,069 64.9%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PROCTER & GAMBLE HEALTH With:   JUBILANT LIFE SCIENCES  DR. DATSONS LABS  WOCKHARDT  GSK PHARMA  PANACEA BIOTECH  

Compare PROCTER & GAMBLE HEALTH With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Stock Markets Remain in Green This Week: Is the Rebound Here?(Podcast)

After a long period of underperformance, stock markets traded in green territory throughout the week. So, is this is a trend reversal and is the bottom forming in the market?

Related Views on News

CADILA HEALTHCARE Announces Quarterly Results (1QFY20); Net Profit Down 28.9% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, CADILA HEALTHCARE has posted a net profit of Rs 3 bn (down 28.9% YoY). Sales on the other hand came in at Rs 35 bn (up 20.8% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

PROCTER & GAMBLE HEALTH Announces Quarterly Results (1QFY20); Net Profit Up 34.3% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, PROCTER & GAMBLE HEALTH has posted a net profit of Rs 441 m (up 34.3% YoY). Sales on the other hand came in at Rs 2 bn (up 6.1% YoY). Read on for a complete analysis of PROCTER & GAMBLE HEALTH's quarterly results.

PROCTER & GAMBLE HEALTH 2017-18 Annual Report Analysis (Annual Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

Here's an analysis of the annual report of PROCTER & GAMBLE HEALTH for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of PROCTER & GAMBLE HEALTH. Also includes updates on the valuation of PROCTER & GAMBLE HEALTH.

CADILA HEALTHCARE Announces Quarterly Results (4QFY19); Net Profit Down 21.0% (Quarterly Result Update)

May 30, 2019 | Updated on May 30, 2019

For the quarter ended March 2019, CADILA HEALTHCARE has posted a net profit of Rs 5 bn (down 21.0% YoY). Sales on the other hand came in at Rs 37 bn (up 14.8% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

MERCK Announces Quarterly Results (4QFY19); Net Profit Up 79.2% (Quarterly Result Update)

May 13, 2019 | Updated on May 13, 2019

For the quarter ended March 2019, MERCK has posted a net profit of Rs 407 m (up 79.2% YoY). Sales on the other hand came in at Rs 2 bn (down 23.3% YoY). Read on for a complete analysis of MERCK's quarterly results.

More Views on News

Most Popular

My 3 Best Small-cap Stocks to Get Rich in this Market Rebound(Profit Hunter)

Oct 14, 2019

This is once in a decade opportunity to make a killing from smallcap rebound.

Finally, Is the Share Price of Yes Bank Ready for a Rebound?(The 5 Minute Wrapup)

Oct 7, 2019

Here's what every individual investor must know about Yes Bank...

Two Stocks to Buy in the Great Indian Festival(Profit Hunter)

Oct 11, 2019

Discounts are not just limited to E-tailers. You can buy stocks at 50% off too. Here are two stocks to buy now.

Buy these 3 Stocks for Rebound Riches

Oct 18, 2019

Equitymaster's smallcap guru and editor of Hidden Treasure, Richa Agarwal, talks to us about the rebound in the stock market, and the best stocks to profit from it. Listen in...

The One Stock I Like in this Market(The 5 Minute Wrapup)

Oct 10, 2019

There are rare periods in markets when you get good quality stocks at attractive valuations. Is this one such period?

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

PROCTER & GAMBLE HEALTH SHARE PRICE


Oct 18, 2019 (Close)

TRACK PROCTER & GAMBLE HEALTH

  • Track your investment in PROCTER & GAMBLE HEALTH with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PROCTER & GAMBLE HEALTH

PROCTER & GAMBLE HEALTH 5-YR ANALYSIS

COMPARE PROCTER & GAMBLE HEALTH WITH

MARKET STATS